This Article Full Text Full Text (PDF) All Versions of this Article: 0008-5472.CAN-08-4531v1 69/12/4937    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Attard, G. Articles by de Bono, J. S. PubMed PubMed Citation Articles by Attard, G. Articles by de Bono, J. S. Related Collections Clinical Research Clinical Research: Response Markers and Mechanisms

Antitumor Activity with CYP17 Blockade Indicates That Castration-Resistant Prostate Cancer Frequently Remains Hormone Driven

Section of Medicine, The Institute of Cancer Research, Sutton, Surrey, United Kingdom

Requests for reprints: Johann S. de Bono, Section of Medicine, The Institute for Cancer Research The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK. Phone: 44-20-8722-4302; Fax: 44-20-8642-7979; E-mail: jdebono{at}icr.ac.uk.

Abiraterone acetate is a potent, selective, and orally bioavailable small molecule inhibitor of CYP17, an enzyme that catalyzes two key serial reactions (17 alpha hydroxylase and 17,20 lyase) in androgen and estrogen biosynthesis. Clinical trials have confirmed that specific inhibition of CYP17 is safe and results in clinically important antitumor activity in up to 70% of castrate patients with advanced prostate cancer resistant to currently available endocrine therapies. These clinical data indicate that castration-resistant prostate cancer frequently remains hormone dependent and has confirmed that this disease should no longer be described as "hormone resistant or refractory". Biomarker studies, including the analysis of ETS gene fusion status, on patients treated with abiraterone acetate may allow enrichment of patients with a sensitive phenotype in future studies of therapeutics targeting CYP17. [Cancer Res 2009;69(12):4937–40]

This article has been cited by other articles:

				A. J. Armstrong and P. G. Febbo Using Surrogate Biomarkers to Predict Clinical Benefit in Men with Castration-Resistant Prostate Cancer: An Update and Review of the Literature Oncologist, August 1, 2009; 14(8): 816 - 827. [Abstract] [Full Text] [PDF]